Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
During persistent viral infections, chronic immune activation, negative immune regulator expression, an elevated interferon signature, and lymphoid tissue destruction correlate with disease progression. We demonstrated that blockade of type I interferon (IFN-I) signaling using an IFN-I receptor neutralizing antibody reduced immune system activation, decreased expression of negative immune regulatory molecules, and restored lymphoid architecture in mice persistently infected with lymphocytic choriomeningitis virus. IFN-I blockade before and after establishment of persistent virus infection resulted in enhanced virus clearance and was CD4 T cell-dependent. Hence, we demonstrate a direct causal link between IFN-I signaling, immune activation, negative immune regulator expression, lymphoid tissue disorganization, and virus persistence. Our results suggest that therapies targeting IFN-I may help control persistent virus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationIMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
Guidotti, L. G., & Chisari, F. V. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100230 · Cited by 811
Cited by
Items 101–200 of 759
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Qi, Y., Liu, B., Sun, Q., Xiong, X., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.578877 · Cited by 146
Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology
Deczkowska, A., Baruch, K., & Schwartz, M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.006 · Cited by 143
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
“Accordingly, this subset of ISGs overlaps with the ISGs elevated during chronic viral infection models in mice and in patients with chronic viral infection [39,40].”
BackgroundYu, X., Cai, B., Wang, M., Tan, P., Ding, X., Wu, J., Li, J., Li, Q., Liu, P., Xing, C., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.001 · Cited by 126
“Previous studies showed that type I IFN signaling inhibits type II IFN (IFN-g) or adaptive immune responses upon malaria and viral infection (Haque et al., 2011; Palomo et al., 2013; Teijaro et al., 2013; Teles et al., 2013; Wilson et al., 2013).”
Targeting of type I interferon in systemic autoimmune diseases
Crow, M. K., Olferiev, M., & Kirou, K. A. (2015) · Translational Research · doi:10.1016/j.trsl.2014.10.005 · Cited by 122
Alveolar macrophages and type I IFN in airway homeostasis and immunity
Divangahi, M., King, I. L., & Pernet, E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.03.005 · Cited by 142
NK Cells and Their Ability to Modulate T Cells during Virus Infections
Cook, K. D., Waggoner, S. N., & Whitmire, J. K. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010604 · Cited by 133
Nakayamada, S., Poholek, A. C., Lu, K. T., Takahashi, H., Kato, M., Iwata, S., Hirahara, K., Cannons, J. L., Schwartzberg, P. L., Vahedi, G., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300675 · Cited by 120
Type III IFNs: Beyond antiviral protection
Kotenko, S. V., Rivera, A., Parker, D., & Durbin, J. E. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101303 · Cited by 132
Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis
Ebert, G., Allison, C. C., Preston, S., Cooney, J. P., Toe, J. G., Stutz, M. D., Ojaimi, S., Baschuk, N., Nachbur, U., Torresi, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502400112 · Cited by 122
Qiu, J., Xu, B., Ye, D., Ren, D., Wang, S., Benci, J. L., Xu, Y., Ishwaran, H., Beltra, J., Wherry, E. J., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00490-y · Cited by 171
Gangaplara, A., Martens, C., Dahlstrom, E., Metidji, A., Gokhale, A. S., Glass, D. D., Lopez-Ocasio, M., Baur, R., Kanakabandi, K., Porcella, S. F., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1006985 · Cited by 115
Buang, N., Tapeng, L., Gray, V., Sardini, A., Whilding, C., Lightstone, L., Cairns, T. D., Pickering, M. C., Behmoaras, J., Ling, G. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22312-y · Cited by 118
Advances in understanding the role of type I interferons in systemic lupus erythematosus
Crow, M. K. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000087 · Cited by 122
“[53], describes the impact of short-term vs.”
Garrison, A. R., Shoemaker, C. J., Golden, J. W., Fitzpatrick, C. J., Suschak, J. J., Richards, M. J., Badger, C. V., Six, C. M., Martin, J. D., Hannaman, D., et al. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005908 · Cited by 118
Responses to Cytokines and Interferons that Depend upon JAKs and STATs
Stark, G. R., Cheon, H., & Wang, Y. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028555 · Cited by 109
“Furthermore, persistent activation of IFN signaling, which depends on STAT1 activation, facilitates persistent lymphocytic choriomeningitis virus (LCMV) infection in mice (Teijaro et al. 2013; Oldstone 2015).”
BackgroundMacrophage Polarization in Virus-Host Interactions
Laura C Miller, Y. S. (2015) · Journal of Clinical and Cellular Immunology · doi:10.4172/2155-9899.1000311 · Cited by 110
Melo, M. B., Nguyen, Q., Cordeiro, C. A., Hassan, M. A., Yang, N., McKell, R., Rosowski, E. E., Julien, L., Butty, V. L., Dardé, M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003779 · Cited by 122
“Importantly, type I interferons can affect infection persistence [65,66], which depends on both timing and magnitude”
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M., Curti, B. D., Wilkins, D. E. C., Alderson, K. A., Sungur, C. M., Ames, E., Mirsoian, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.023 · Cited by 106
“Other studies suggest that elevated cytokine concentrations might play a role in propagating the exhaustion that occurs during chronic infections (Teijaro et al., 2013;Wilson et al., 2013).”
BackgroundLi, G., Cheng, M., Nunoya, J.-I., Cheng, L., Guo, H., Yu, H., Liu, Y.-J., Su, L., & Zhang, L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004291 · Cited by 115
“Two recent reports showed that blocking IFN-I signaling during LCMV persistent infection could improve antiviral T cell response and accelerate clearance of chronic LCMV infection via an IL-10related mechanism [66,67].”
Dendritic cell dysregulation during HIV ‐1 infection
Miller, E., & Bhardwaj, N. (2013) · Immunological Reviews · doi:10.1111/imr.12082 · Cited by 127
“Recent work with LCMV infection in mice supports these observations and implicates a potential therapeutic role for blockade of type I interferon signaling in chronic infection (188, 189).”
BackgroundType I IFN signaling in CD8– DCs impairs Th1-dependent malaria immunity
Haque, A., Best, S. E., Montes de Oca, M., James, K. R., Ammerdorffer, A., Edwards, C. L., de Labastida Rivera, F., Amante, F. H., Bunn, P. T., Sheel, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70698 · Cited by 113
“Type I IFNs are crucial for protection against viruses but can facilitate survival of many pathogens, such as Listeria (1, 2), Mycobac-teria (3–7), Staphylococci (8), and Lymphocytic choriomen ingitis virus (9, 10), as well as protozoan parasites, such as Leishmania (11) and Plasmodium (12).”
Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Fallet, B., Narr, K., Ertuna, Y. I., Remy, M. M., Sommerstein, R., Cornille, K., Kreutzfeldt, M., Pagé, N., Zimmer, G., Geier, F., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah6817 · Cited by 119
“The essential antiviral role of IFN-I may preclude the success of αIFNARbased immunomodulatory therapy ((15, 16, 29), Fig.”
Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions
Kervevan, J., & Chakrabarti, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020523 · Cited by 126
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 131
Smith, D. R., Hollidge, B., Daye, S., Zeng, X., Blancett, C., Kuszpit, K., Bocan, T., Koehler, J. W., Coyne, S., Minogue, T., et al. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005296 · Cited by 107
“monoclonal antibodies targeting either IFN-Is directly or the IFN-I receptor [41-43].”
BackgroundType I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 122
Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei
Kessler, B., Rinchai, D., Kewcharoenwong, C., Nithichanon, A., Biggart, R., Hawrylowicz, C. M., Bancroft, G. J., & Lertmemongkolchai, G. (2017) · Scientific Reports · doi:10.1038/srep42791 · Cited by 117
Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
Levin, D., Schneider, W. M., Hoffmann, H.-H., Yarden, G., Busetto, A. G., Manor, O., Sharma, N., Rice, C. M., & Schreiber, G. (2014) · Science Signaling · doi:10.1126/scisignal.2004998 · Cited by 113
Type I Interferons as Regulators of Human Antigen Presenting Cell Functions
Gessani, S., Conti, L., Cornò, M. D., & Belardelli, F. (2014) · Toxins · doi:10.3390/toxins6061696 · Cited by 119
“Specifically, a reduced antiviral response has been observed in mice persistently infected with lymphocytic choriomeningitis virus (LCMV), and this unresponsiveness has been associated with the IFN-mediated induction of IL-10 and programmed cell death 1 ligand 1 (PD-L1) expression in DCs [76,77].”
BackgroundThe crucial regulatory role of type I interferon in inflammatory diseases
Ji, L., Li, T., Chen, H., Yang, Y., Lu, E., Liu, J., Qiao, W., & Chen, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01188-z · Cited by 121
“Studies have shown that blocking IFN-I signaling, either through the administration of antibodies or receptor deficiency, can enhance the control of chronic infection with LCMV clone 13, mediated by CD4 + T cells [231].”
BackgroundRossi, M., Castiglioni, P., Hartley, M., Eren, R. O., Prével, F., Desponds, C., Utzschneider, D. T., Zehn, D., Cusi, M. G., Kuhlmann, F., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621447114 · Cited by 111
“To test this possibility, we coinfected mice with LgyLRV1 parasites and LCMV Armstrong, an arenavirus, which induces a potent type I IFN response (37).”
MethodOsokine, I., Snell, L. M., Cunningham, C. R., Yamada, D. H., Wilson, E. B., Elsaesser, H. J., de la Torre, J. C., & Brooks, D. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401662111 · Cited by 113
“To evaluate the role of IFN-I in modulating Th1 differentiation during persistent infection, we treated animals with an antibody that blocks IFN-I receptor (IFNR) signaling in vivo (21, 22).”
BackgroundSARS-CoV and IFN: Too Little, Too Late
Kindler, E., & Thiel, V. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.012 · Cited by 101
“…also have immunosuppressive potential, accompanied with chronic immune activation during persistent lymphocytic choriomeningitis virus infection (Teijaro et al., 2013; Wilson et al., 2013), or pathogenic potential, manifested by increased lung damage during acute influenza virus infection…”
BackgroundDual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation
King, C., & Sprent, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.003 · Cited by 114
“IFN-I is important for the differentiation of Tfh cells, acting both through direct stimulation of Tfh precursors [17] and also by eliciting cytokine generation from DCs [53].”
InfluentialVukmanovic-Stejic, M., Chambers, E. S., Suárez-Fariñas, M., Sandhu, D., Fuentes-Duculan, J., Patel, N., Agius, E., Lacy, K. E., Turner, C. T., Larbi, A., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.032 · Cited by 103
“Type I interferon has been shown to interfere with antigenspecific T-cell responses, and excessive levels of these mediators impair the clearance of both viral and mycobacterial infections in mice in vivo.(36,37) In the present studywe also found a strong type I interferon signature in the skin of old subjects after s…”
Ng, C. T., Snell, L. M., Brooks, D. G., & Oldstone, M. B. A. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.014 · Cited by 100
“During Cl-13 infection, mice exhibit severe lymphoid disorganization concomitant with loss of T cell function and immune suppression (Mueller et al., 2007b; Teijaro et al., 2013; Tishon et al., 1993).”
BackgroundResultInfluentialSelf-citationde, M. M., Kumar, R., Rivera, F. D. L., Amante, F. H., Sheel, M., Faleiro, R. J., Bunn, P. T., Best, S. E., Beattie, L., Ng, S. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.015 · Cited by 111
“…but can also promote pathogen survival by suppressing immunity during infections, such as those caused by lymphocytic choriomeningitis virus (Teijaro et al., 2013; Wilson et al., 2013), influenza (Arimori et al., 2013), Mycobacteria (Antonelli et al., 2010; Berry et al., 2010; Desvignes et…”
BackgroundMalireddi, R. K. S., & Kanneganti, T. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00077 · Cited by 113
“It will be essential to study the contribution of type I IFN in pyroptosis induction during B. anthracis infection and investigate whether type I IFN can promote apoptosis of neutrophils and initiate other possible detrimental effects.”
BackgroundBystander Chronic Infection Negatively Impacts Development of CD8+ T Cell Memory
Stelekati, E., Shin, H., Doering, T. A., Dolfi, D. V., Ziegler, C. G., Beiting, D. P., Dawson, L., Liboon, J., Wolski, D., Ali, M.-A. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.010 · Cited by 97
“Moreover, blockade of IFNAR during chronic viral infection has recently been found to paradoxically benefit antiviral adaptive immune responses (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundLong-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155
Stelekati, E., Chen, Z., Manne, S., Kurachi, M., Ali, M.-A., Lewy, K., Cai, Z., Nzingha, K., McLane, L. M., Hope, J. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.038 · Cited by 96
“Although inflammatory cytokines are essential for optimal T cell priming, persistent inflammation, and particularly type I IFN signaling during chronic infection, are detrimental for T cell differentiation (Stelekati et al., 2014; Teijaro et al., 2013; Wilson et al., 2013).”
Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
Bosinger, S. E., & Utay, N. S. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0244-6 · Cited by 100
Chyuan, I., Tzeng, H., & Chen, J.-Y. (2019) · Cells · doi:10.3390/cells8090963 · Cited by 107
“When the type I IFN signaling is blocked with anti-IFNAR antibodies, the immunotolerant state is reversed, DCs are further stimulated, and virus-specific CD4+ T cell immunity is enhanced, which consequently improves infection control [56,57].”
BackgroundShon, W.-J., Lee, Y.-K., Shin, J. H., Choi, E. Y., & Shin, D.-M. (2015) · Scientific Reports · doi:10.1038/srep17305 · Cited by 105
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., & Ahmed, R. (2016) · Journal of Virology · doi:10.1128/jvi.00798-16 · Cited by 96
CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 112
“After CD8 T cell exhaustion is established, IFNα/β help enhance the antiviral capacity of CD8 T cells [57].”
BackgroundInterferon‐alpha, immune activation and immune dysfunction in treated HIV infection
Cha, L., Berry, C., Nolan, D. A., Castley, A., Fernández, S., & French, M. A. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.1 · Cited by 97
Cheng, L., Yu, H., Li, G., Li, F., Ma, J., Li, J., Chi, L., Zhang, L., & Su, L. (2017) · JCI Insight · doi:10.1172/jci.insight.94366 · Cited by 100
“During chronic LCMV infection in mice, blocking IFN-I signaling with an anti-IFNAR1 mAb can enhance antiviral immune responses and prevent or accelerate clearance of persistent LCMV infection in mice (16, 17).”
BackgroundFraietta, J. A., Mueller, Y. M., Yang, G., Boesteanu, A. C., Gracias, D. T., Do, D. H., Hope, J. L., Kathuria, N., McGettigan, S. E., Lewis, M. G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003658 · Cited by 97
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus
Ebert, G., Preston, S., Allison, C. C., Cooney, J. P., Toe, J. G., Stutz, M. D., Ojaimi, S., Scott, H. W., Baschuk, N., Nachbur, U., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502390112 · Cited by 102
“Clear immune effects were observed in LCMV-infected mice, consistent with published reports (14, 15).”
ResultModulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes
Feng, E., Balint, E., Poznanski, S. M., Ashkar, A. A., & Loeb, M. (2021) · Cells · doi:10.3390/cells10030708 · Cited by 82
The role of type I interferons in intestinal infection, homeostasis, and inflammation
Cho, H., & Kelsall, B. L. (2014) · Immunological Reviews · doi:10.1111/imr.12195 · Cited by 102
“Deleterious immunosuppressive effects of IFN-I signaling during persistent lymphocytic choriomeningitis virus (LCMV) infection have been recently described (179, 180).”
BackgroundWu, J., Tian, L., Yu, X. H., Pattaradilokrat, S., Li, J., Wang, M., Yu, W., Qi, Y., Zeituni, A. E., Nair, S. C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316467111 · Cited by 97
“Recent data from viral infection suggested that chronic high levels of IFN-I could lead to immunosuppression and prolonged infection (48, 49).”
BackgroundKey, F. M., Lewis, B. P., Dennis, M. Y., Huerta‐Sánchez, E., Tang, W., Prokunina‐Olsson, L., Nielsen, R., & Andrés, A. M. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004681 · Cited by 100
“It is perhaps surprising that suppression of an antiviral protein results in improved viral clearance, although it has for example been shown that during chronic infection blockage of persistent signaling of IFN I (a different type of interferon) can improve viral clearance [37,38].”
Rexach, J. E., Polioudakis, D., Yin, A., Swarup, V., Chang, T. S., Nguyen, T., Sarkar, A., Chen, L., Huang, J., Lin, L.-C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108398 · Cited by 94
“Type I IFN is a critical driver of immune suppression and tolerance in certain chronic viral infections (Teijaro et al., 2013).”
BackgroundInterferons and HIV Infection: The Good, the Bad, and the Ugly
Utay, N. S., & Douek, D. C. (2016) · Pathogens and Immunity · doi:10.20411/pai.v1i1.125 · Cited by 86
Xin, G., Zander, R., Schauder, D., Yao, C., Weinstein, J. S., Drobyski, W. R., Tarakanova, V. L., Craft, J. E., & Cui, W. (2018) · Nature Communications · doi:10.1038/s41467-018-07492-4 · Cited by 98
Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 97
“It is well documented that type I IFNs (IFNIs) are induced at high levels during viral infections, while the production of IFN- Is is much lower in a tumor setting (32, 33).”
BackgroundMoseman, E. A., Wu, T., de la Torre, J. C., Schwartzberg, P. L., & McGavern, D. B. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah3565 · Cited by 91
Interferons as Essential Modulators of Atherosclerosis
Boshuizen, M. C. S., & de Winther, M. P. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305464 · Cited by 97
Tomasello, E., Pollet, É., Manh, T. V., Uzé, G., & Dalod, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00526 · Cited by 94
“Proc Natl Acad Sci U S A (2009) 106(13):5306–11.”
BackgroundInfluentialBohne, F., Londoño, M., Benítez, C., Miquel, R., Martínez‐Llordella, M., Russo, C., Ortíz, C., Bonaccorsi‐Riani, E., Brander, C., Bauer, T., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008793 · Cited by 91
Iwata, S., Mikami, Y., Sun, H.-W., Brooks, S. R., Jankovic, D., Hirahara, K., Onodera, A., Shih, H.-Y., Kawabe, T., Jiang, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.05.005 · Cited by 90
“As a control, we also analyzed T cells from wild-type and Tbx21 / mice infected with lymphocytic choriomeningitis virus (LCMV), a viral infection known to induce a dynamic type I IFN response (Teijaro et al., 2013; Wilson et al., 2013; Zhou et al., 2010).”
Plasmacytoid dendritic cells promote HIV-1–induced group 3 innate lymphoid cell depletion
Zhang, Z., Cheng, L., Zhao, J., Li, G., Zhang, L., Chen, W., Nie, W., Reszka-Blanco, N., Wang, F., & Su, L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82124 · Cited by 91
HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction
Akiyama, H., Miller, C. M., Ettinger, C. R., Belkina, A. C., Snyder-Cappione, J. E., & Gummuluru, S. (2018) · Nature Communications · doi:10.1038/s41467-018-05899-7 · Cited by 96
Cellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 95
Metidji, A., Rieder, S. A., Glass, D. D., Cremer, I., Punkosdy, G. A., & Shevach, E. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500036 · Cited by 87
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Spaapen, R. M., Leung, M. Y. K., Fuertes, M. B., Kline, J. P., Zhang, L., Zheng, Y., Fu, Y.-X., Luo, X., Cohen, K. S., & Gajewski, T. F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401109 · Cited by 85
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 96
Reduction of HBV replication prolongs the early immunological response to IFNα therapy
Tan, A. T., Hoang, L. T., Chin, D. J., Rasmussen, E., Lopatin, U. A., Hart, S., Bitter, H., Chu, T., Gruenbaum, L. M., Ravindran, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.020 · Cited by 92
“Interestingly, work performed in a chronic murine LCMV infection model illustrates a dichotomous effect of IFNa [23,24].”
BackgroundClonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection
Kasmani, M. Y., Zander, R., Chung, H. K., Chen, Y., Khatun, A., Damo, M., Topchyan, P., Johnson, K. E., Levashova, D., Burns, R., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220679 · Cited by 87
“, 2013), we reasoned that IRF7may play a more prominent role in the setting of persistent infection, given that type I IFN production is augmented during chronic viral infection, and ISGs remain elevated for several weeks after LCMV Cl13 infection (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundThe Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?
Wu, W., & Metcalf, J. P. (2020) · Journal of Innate Immunity · doi:10.1159/000508379 · Cited by 87
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 94
“Although IRF7 induction can potentiate CAR-T cell activation and induce antitumor activity 47 , in certain contexts, type I IFN signaling can also orchestrate T cell immunosuppression 48,49 andinduceapoptosisonCAR-Tcells 50 .”
Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors
Brisse, M. E., & Ly, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00372 · Cited by 87
“Mice infected with the OW LCMV, which is capable of maintaining persistent infection with low levels of IFN1 signaling (225, 226), display”
BackgroundTumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection
Beyer, M., Abdullah, Z., Chemnitz, J. M., Maisel, D., Sander, J., Lehmann, C., Thabet, Y., Shinde, P. V., Schmidleithner, L., Köhne, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3399 · Cited by 86
AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
Schmid, E. T., Pang, I. K., Carrera Silva, E. A., Bosurgi, L., Miner, J. J., Diamond, M. S., Iwasaki, A., & Rothlin, C. V. (2016) · eLife · doi:10.7554/elife.12414 · Cited by 81
“Type I IFNs were identified based on their ability to inhibit the propagation of viruses (Isaacs and Lindenmann, 1957; Taniguchi et al., 1980).”
BackgroundThe Dual Role of Exosomes in Hepatitis A and C Virus Transmission and Viral Immune Activation
Longatti, A. (2015) · Viruses · doi:10.3390/v7122967 · Cited by 86
“Although type I interferons are generally considered to be a major first line of host defense after viral infection recent studies suggest that sustained interferon production may in some way contribute to viral persistence [62–64].”
BackgroundThe Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis
Wacleche, V. S., Tremblay, C. L., Routy, J., & Ancuța, P. (2018) · Viruses · doi:10.3390/v10020065 · Cited by 94
“In addition, CCR2low/neg classical monocytes suppressed CD8+ T-cells proliferation and IFN-γ release, indicating that these monocytes may postpone the development of the antiviral responses.”
BackgroundInfluentialLindquist, M. E., Zeng, K. X., Altamura, L. A., Daye, S. P., Delp, K. L., Blancett, C. D., Coffin, K. M., Koehler, J. W., Coyne, S. R., Shoemaker, C. J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01083-18 · Cited by 81
“In addition to their usefulness in severe-disease models, antibody blockade of IFN-I signaling was shown to increase viral clearance and control of a persistent lymphocytic choriomeningitis virus infection by altering the immune response (54, 55).”
BackgroundNewson, J., Motwani, M. P., Kendall, A. C., Nicolaou, A., Muccioli, G. G., Alhouayek, M., Bennett, M., Van De Merwe, R., James, S., De Maeyer, R. P. H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.098 · Cited by 77
“, 1997; Segal, 1996) or failure to engage adaptive immunity (Teijaro et al., 2013; Wilson et al., 2013) can also lead to chronic inflammation and autoimmunity.”
BackgroundGaly, A. S. D., Menegatti, S., Fuentealba, J. R., Perrin, L., Lucibello, F., Helft, J., Darbois, A., Saitakis, M., Tosello, J., Rookhuizen, D. C., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe8219 · Cited by 84
Humanized Mouse Models for Human Immunodeficiency Virus Infection
Marsden, M. D., & Zack, J. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041703 · Cited by 82
“However, continuous type I IFN signaling in chronic viral infections can also contribute to persistent immune activation and can have deleterious effects on antiviral responses (51, 55).”
BackgroundInterfering with immunity: detrimental role of type I IFNs during infection
Stifter, S. A., & Feng, C. G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402794 · Cited by 78
Nuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA
Liu, S., Jiang, M., Wang, W., Liu, W., Song, X., Ma, Z., Zhang, S., Liu, L., Liu, Y., & Cao, X. (2017) · Nature Immunology · doi:10.1038/s41590-017-0003-0 · Cited by 81
DNA sensing via the cGAS/STING pathway activates the immunoproteasome and adaptive T‐cell immunity
Wang, X., Zhang, H., Wang, Y., Bramasole, L., Guo, K., Mourtada, F., Meul, T., Hu, Q., Viteri, V., Kammerl, I. E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022110597 · Cited by 81
Zander, R. A., Guthmiller, J. J., Graham, A. C., Pope, R. L., Burke, B. E., Carr, D. J. J., & Butler, N. S. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005945 · Cited by 76
Cunningham, C. R., Champhekar, A. S., Tullius, M. V., Dillon, B. J., Zhen, A., la Fuente, J. R. O. D., Herskovitz, J., Elsaesser, H. J., Snell, L. M., Wilson, E. B., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005356 · Cited by 87
“Simultaneous with its critical antiviral role, IFN-I signaling led to a surprising amount of the immune dysfunctions associated with viral persistence including expression of IL-10 and PDL1 [10, 11].”
BackgroundTherapeutic Depletion of Natural Killer Cells Controls Persistent Infection
Waggoner, S. N., Daniels, K. A., & Welsh, R. M. (2013) · Journal of Virology · doi:10.1128/jvi.03002-13 · Cited by 73
“This parallels recently published studies showing that early blockade of type 1 IFN activity enhanced viral loads but blockade of IFN activity later on, during persistence, reduced viral loads (16, 17).”
BackgroundResultThe microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection
Moffett, H. F., Cartwright, A. N. R., Kim, H.-J., Godec, J., Pyrdol, J., Äijö, T., Martinez, G. J., Rao, A., Lu, J., Golub, T. R., et al. (2017) · Nature Immunology · doi:10.1038/ni.3755 · Cited by 67
Waffarn, E., Hastey, C. J., Dixit, N., Choi, Y. S., Cherry, S. R., Kalinke, U., Simon, S. I., & Baumgarth, N. (2015) · Nature Communications · doi:10.1038/ncomms9991 · Cited by 79
IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection
Huang, Z., Žák, J., Pratumchai, I., Shaabani, N., Vartabedian, V. F., Nguyen, N., Wu, T., Xiao, C., & Teijaro, J. R. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190173 · Cited by 73
“Results IFNα/β receptor 1 (IFNAR1) blockade results in expansion of TCF1hi virus-specific CD8+ T cells Blockade of IFN-I signaling during persistent LCMV infection enhances T cell–mediated control of persistent virus infection (Teijaro et al., 2013; Wilson et al., 2013; Ng et al., 2015).”
BackgroundSelf-citationCook, L. E., Locke, M. C., Young, A. R., Monte, K. J., Hedberg, M. L., Shimak, R. M. K., Sheehan, K. C. F., Novack, D. V., Diamond, M., & Lenschow, D. J. (2019) · Journal of Virology · doi:10.1128/jvi.00841-19 · Cited by 74
Self-citationEarly type I IFN blockade improves the efficacy of viral vaccines
Palacio, N. M., Dangi, T., Chung, Y. R., Wang, Y., Loredo-Varela, J.-L., Zhang, Z., & Penaloza‐MacMaster, P. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191220 · Cited by 72
Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice
Kalia, V., Yuzefpolskiy, Y., Vegaraju, A., Xiao, H., Baumann, F. M., Jatav, S., Church, C. D., Prlic, M., Jha, A., Nghiem, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6006 · Cited by 76
Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 76
TRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation
Ferri, F., Parcelier, A., Petit, V., Gallouet, A.-S., Lewandowski, D., Dalloz, M., van den Heuvel, A., Kolovos, P., Soler, E., Squadrito, M. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms9900 · Cited by 70
Brown, M. C., Mosaheb, M., Mohme, M., McKay, Z. P., Holl, E. K., Kastan, J. P., Yang, Y., Beasley, G. M., Hwang, E., Ashley, D. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22088-1 · Cited by 73
Type I interferon is a therapeutic target for virus-induced lethal vascular damage
Baccalà, R., Welch, M. J., González‐Quintial, R., Walsh, K. B., Teijaro, J. R., Nguyen, A., Ng, C. T., Sullivan, B. M., Zarpellon, A., Ruggeri, Z. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408148111 · Cited by 70
“Although IFN-I has long been thought to protect the host from viral infections due to potent antiviral and immune response-promoting effects, recent studies have implicated these cytokines in harming the host in a number of viral and bacterial infections (24, 25, 39, 40).”
BackgroundSelf-citationCook, K. D., Kline, H. C., & Whitmire, J. K. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4hi1214-594r · Cited by 79
“A set of papers recently identified an inhibitory role for type I IFN in limiting antiviral T cell responses during the chronic stage of LCMV infection [9, 10].”
Background
Metadata
- Authors
- Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A.
- Affiliations
- Scripps Research Institute (US)
- Washington University in St. Louis (US)
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
- Corresponding author
- Teijaro, John R.
- Ng, Cherie
- Oldstone, Michael B. A.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3640797
- OpenAlex
- W2024556668
- Cited by
- 755
- References
- 38
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 39 · 2023: 40 · 2022: 42 · 2021: 49 · 2020: 56 · 2019: 55 · 2018: 55 · 2017: 73 · 2016: 86 · 2015: 80 · 2014: 71 · 2013: 37
- FWCI
- 50.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ns041219-10, 5t32ai007354-30)
- National Heart, Lung, and Blood Institute (HL007195, T32HL007195)
- National Cancer Institute (R01CA043059, CA-43059, R37CA043059)
- National Institute of Allergy and Infectious Diseases (AI-077719, AI09484, AI-047140, R01AI009484, AI007354, R01AI047140, T32-AI007354., R56AI077719, R01AI077719, U54AI057160)
- National Institute of Neurological Disorders and Stroke (T32-NS041219, NS-041219)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- lymphocytic choriomeningitis virus, viral persistence, type I interferon signaling, immune activation, negative immune regulation, CD4+ T cells, viral clearance, antiviral therapy
- MeSH terms
- Animals, Antibodies, Viral, Arenaviridae Infections, Dendritic Cells, Female, Immune Tolerance, Interferon Type I, Lymphocytes, Lymphocytic choriomeningitis virus, Male, Mice, Inbred C57BL, Spleen, Viremia, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.